The Satera Ablation System unilaterally ablates the Greater Splanchnic Nerve to calm sympathetic activity with the goal of normalizing volume balance, increasing cardiac functional capacity and improving symptoms for HF patients.
Location: United States
Employees: 11-50
Total raised: $32M
Founded date: 2014
Investors 2
| Date | Name | Website |
| 12.10.2025 | KOFA Healt... | kofahealth... |
| - | Action Pot... | actionpote... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.10.2025 | Series A | $32M | Earlybird ... |
Mentions in press and media 4
| Date | Title | Description |
| 01.10.2025 | Axon Therapies: $32 Million Series A Secured For Developing Heart Failure Treatments | Axon Therapies, a pioneering company in the medical device field, has announced the closure of an oversubscribed $32 million Series A funding round, focused on developing innovative treatments for heart failure. This funding round was co-le... |
| 26.09.2025 | Axon Therapies Raises $32M in Funding | Co-founder Zoar Engelman, PhD, appointed CEO of Axon Therapies Axon Therapeutics, a NYC-based clinical-stage medical device company, raised $32M in funding. The round was led by Earlybird Venture Capital and Santé Ventures, with participati... |
| 07.11.2012 | Biopharmaceutical startup developing heart failure therapeutic raises more than $28M | Solution/product: The drug development company’s lead product in its pipeline, CXL-1020 is a compound designed to treat acute decompensated heart failure, the top reason for hospitalization among adults aged 65 or older in the US. The condi... |
| - | Axon Therapies | “Axon is pioneering a frontline therapy that leverages Splanchnic Ablation for Volume Management (SAVM) to treat a root cause of heart failure.” |